Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Journal
-
- The Lancet Oncology
-
The Lancet Oncology 20 (9), 1239-1251, 2019-09
Elsevier BV
- Tweet
Details 詳細情報について
-
- CRID
- 1362262945370285696
-
- ISSN
- 14702045
-
- Data Source
-
- Crossref